A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With…The purpose of this study is to observe the safety of agalsidase alfa in Canadian patients with Fabry disease. Recruiting Principal Investigator Sandra SirrsArea Vancouver
Canadian Fabry Disease Initiative (CFDI) Enzyme Replacement Therapy (ERT) StudyCFDI STUDY with ENZYME REPLACEMENT THERAPY (ERT)Recruiting Principal Investigator Sandra SirrsBody Locations and Systems BrainArea VancouverAge 5-85
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry DiseaseThe purpose of this study is to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease. Recruiting Principal Investigator Sandra SirrsArea VancouverAge 18 and above
